Page last updated: 2024-08-24

atorvastatin and Kawasaki Disease

atorvastatin has been researched along with Kawasaki Disease in 8 studies

Research

Studies (8)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	7 (87.50)	24.3611
2020's	1 (12.50)	2.80

Authors

Authors	Studies
Burns, JC; He, M; Hoffman, HM; Kim, J; Shimizu, C; Shyy, JY; Tremoulet, AH	1
Anderson, MS; Bainto, E; Best, BM; Burns, JC; Cohen, HJ; Dominguez, SR; Duxbury, EH; Franco, A; Glodé, MP; He, F; Heizer, H; Jain, S; Jone, PN; Padilla, RL; Pancheri, J; Printz, B; Shimizu, C; Tremoulet, AH; Whitin, JC	1
Chahal, N; Manlhiot, C; McCrindle, BW; Niedra, E; Yeung, RS	1
Tremoulet, AH	2
Manlhiot, C; McCrindle, BW	1
Burns, JC; Chen, Z; He, M; Jain, MK; Martin, M; Sangwung, P; Shimizu, C; Shyy, JY; Tremoulet, AH; Woo, B; Zhang, J	1
Blankier, S; Ito, S; McCrindle, BW; Yeung, RS	1

Trials

2 trial(s) available for atorvastatin and Kawasaki Disease

Article	Year
Phase I/IIa Trial of Atorvastatin in Patients with Acute Kawasaki Disease with Coronary Artery Aneurysm. The Journal of pediatrics, 2019, Volume: 215 Topics: Administration, Oral; Adolescent; Atorvastatin; Child; Child, Preschool; Coronary Aneurysm; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mucocutaneous Lymph Node Syndrome	2019
miR-483 Targeting of CTGF Suppresses Endothelial-to-Mesenchymal Transition: Therapeutic Implications in Kawasaki Disease. Circulation research, 2017, Jan-20, Volume: 120, Issue:2 Topics: Animals; Atorvastatin; Cattle; Child, Preschool; Connective Tissue Growth Factor; Dose-Response Relationship, Drug; Endothelial Cells; Epithelial-Mesenchymal Transition; Female; Gene Targeting; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infant; Kruppel-Like Factor 4; Male; Mice; Mice, Transgenic; MicroRNAs; Mucocutaneous Lymph Node Syndrome	2017

Article

Year

Phase I/IIa Trial of Atorvastatin in Patients with Acute Kawasaki Disease with Coronary Artery Aneurysm.

The Journal of pediatrics, 2019, Volume: 215

Topics: Administration, Oral; Adolescent; Atorvastatin; Child; Child, Preschool; Coronary Aneurysm; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mucocutaneous Lymph Node Syndrome

2019

miR-483 Targeting of CTGF Suppresses Endothelial-to-Mesenchymal Transition: Therapeutic Implications in Kawasaki Disease.

Circulation research, 2017, Jan-20, Volume: 120, Issue:2

Topics: Animals; Atorvastatin; Cattle; Child, Preschool; Connective Tissue Growth Factor; Dose-Response Relationship, Drug; Endothelial Cells; Epithelial-Mesenchymal Transition; Female; Gene Targeting; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infant; Kruppel-Like Factor 4; Male; Mice; Mice, Transgenic; MicroRNAs; Mucocutaneous Lymph Node Syndrome

2017

Other Studies

6 other study(ies) available for atorvastatin and Kawasaki Disease

Article	Year
RNA Sequencing Reveals Beneficial Effects of Atorvastatin on Endothelial Cells in Acute Kawasaki Disease. Journal of the American Heart Association, 2022, 07-19, Volume: 11, Issue:14 Topics: Atorvastatin; Endothelial Cells; Human Umbilical Vein Endothelial Cells; Humans; Immunoglobulins, Intravenous; Inflammation; Infliximab; Mucocutaneous Lymph Node Syndrome; Sequence Analysis, RNA	2022
Atorvastatin safety in Kawasaki disease patients with coronary artery aneurysms. Pediatric cardiology, 2014, Volume: 35, Issue:1 Topics: Administration, Oral; Anthropometry; Anti-Inflammatory Agents; Atorvastatin; Canada; Child; Child Development; Cholesterol; Coronary Aneurysm; Coronary Vessels; Dose-Response Relationship, Drug; Drug Monitoring; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Liver Function Tests; Male; Medical Records, Problem-Oriented; Mucocutaneous Lymph Node Syndrome; Pyrroles; Retrospective Studies	2014
Comment on atorvastatin safety in kawasaki disease patients with coronary artery aneurysms. Pediatric cardiology, 2014, Volume: 35, Issue:1 Topics: Atorvastatin; Child Development; Coronary Aneurysm; Coronary Vessels; Female; Heptanoic Acids; Humans; Inflammation; Male; Mucocutaneous Lymph Node Syndrome; Pyrroles	2014
Author reply to comment on "atorvastatin safety in Kawasaki disease patients with coronary artery aneurysms". Pediatric cardiology, 2014, Volume: 35, Issue:1 Topics: Atorvastatin; Child Development; Coronary Aneurysm; Coronary Vessels; Female; Heptanoic Acids; Humans; Inflammation; Male; Mucocutaneous Lymph Node Syndrome; Pyrroles	2014
The role of statins in inflammatory vasculitides. Autoimmunity, 2015, Volume: 48, Issue:3 Topics: Adaptive Immunity; Adolescent; Adult; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Atorvastatin; Behcet Syndrome; Child; Child, Preschool; Clinical Trials as Topic; Drug Repositioning; Humans; Immunity, Innate; Infant; Inflammation; Mucocutaneous Lymph Node Syndrome	2015
The role of atorvastatin in regulating the immune response leading to vascular damage in a model of Kawasaki disease. Clinical and experimental immunology, 2011, Volume: 164, Issue:2 Topics: Animals; Antigens, Bacterial; Arteritis; Atorvastatin; Cell Wall; Coronary Aneurysm; Coronary Disease; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Induction; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunologic Factors; Lacticaseibacillus casei; Lymphocyte Activation; MAP Kinase Signaling System; Matrix Metalloproteinase 9; Mevalonic Acid; Mice; Mice, Inbred C57BL; Mucocutaneous Lymph Node Syndrome; Pyrroles; Specific Pathogen-Free Organisms; Superantigens; Tumor Necrosis Factor-alpha	2011